Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as an adjuvant treatment for Head and neck cancer after surgery